LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...

LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare ...

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all progra ...

Keros' Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1, 2024. Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain an active Board member. Jean-Jacques Bienaimé will serve as the Lead Independent Director of the Board, effective July 1, 2024. "I am honored to expand my role with Keros as the next Chair of its Board. I look forward to working with and leading our Board, which is comprised of directors with diverse ba ...

Keros' Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1, 2024. Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain an active Board member. Jean-Jacques Bienaimé will serve as the Lead Independent Director of the Board, effective July 1, 2024. "We're pleased to welcome Jas to the Board Chair position," said Dr. Gordon. "The Board and I have worked closely with and observed Jas in his role as director and as CEO. We b ...

Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigue Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reduct ...

LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it presented additional data from its two ongoing Phase 2 clinical trials of elritercept (KER-050), one in ...

Core Viewpoint - Keros Therapeutics, Inc. is advancing its clinical programs, receiving positive FDA feedback for its KER-050 program, and plans to discuss its pipeline in an upcoming conference call [2][3]. Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional TGF-ß signaling [3]. - The company is a leader in understanding the TGF-ß family of proteins, which regulate the growth and maintenance of various tissues [3]. - Keros' lead product candidate, KER-050 (elritercept), targets low blood cell counts in patients with myelodysplastic syndromes (MDS) and myelofibrosis [3]. - The second product candidate, KER-012 (cibotercept), is aimed at treating pulmonary arterial hypertension (PAH) and cardiovascular disorders [3]. - Keros is also developing KER-065 for obesity and neuromuscular diseases [3]. Recent Developments - Keros received positive feedback from the FDA regarding the design and endpoints for the pivotal Phase 3 clinical trial of KER-050 in MDS patients [2]. - The company expects to complete enrollment for its ongoing Phase 2 TROPOS trial of KER-012 in PAH patients by the fourth quarter of 2024 [2]. Upcoming Events - Keros will host a corporate update conference call and webcast on June 17, 2024, at 8:00 a.m. Eastern time [1][2].

Company Overview - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins [1][4] - The company is recognized as a leader in understanding the TGF-ß family of proteins, which are crucial for the growth, repair, and maintenance of various tissues [4] Recent Developments - Keros announced the appointment of Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024 [1] - The CEO, Jasbir Seehra, expressed confidence in Bienaimé's extensive experience in biotechnology and pharmaceuticals, which will be beneficial for the company's growth and product pipeline [2] Leadership Background - Jean-Jacques Bienaimé previously served as CEO of BioMarin Pharmaceutical Inc. from May 2005 until his retirement in December 2023 [2] - He has held leadership roles at Genencor, Inc. and Sangstat Medical Corporation, and has experience in senior management at Rhône-Poulenc Rorer Pharmaceuticals [2] - Bienaimé holds an M.B.A. from the Wharton School and a degree in economics from the École Supérieure de Commerce de Paris [3] Product Pipeline - Keros' lead product candidate, KER-050 (elritercept), targets low blood cell counts, including anemia and thrombocytopenia, in patients with MDS and myelofibrosis [4] - The second candidate, KER-012 (cibotercept), is aimed at treating pulmonary arterial hypertension and cardiovascular disorders [4] - KER-065 is being developed for obesity and neuromuscular diseases [4]

LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Boa ...